Printed from https://ideas.repec.org/s/spr/eujhec7.html
Content
August 2013, Volume 14, Issue 4
- 615-627 What accounts for the regional differences in the utilisation of hospitals in Germany?
by Boris Augurzky & Thomas Kopetsch & Hendrik Schmitz - 629-638 Palliative treatment of colorectal cancer in Germany: cost of care and quality of life
by Martin Emmert & Katharina Pohl-Dernick & Axel Wein & Frank Dörje & Susanne Merkel & Frank Boxberger & Gudrun Männlein & Robert Joost & Hans-Detlev Harich & Roland Thiemann & Christof Lamberti & Markus Neurath & Werner Hohenberger & Oliver Schöffski - 639-653 Measuring Worksite Health Promotion Programs: an application of Structural Equation Modeling with ordinal data
by Fredrik Ødegaard & Pontus Roos - 655-665 The economic burden of atherothrombosis in Greece: results from the THESIS study
by Nikos Maniadakis & Georgia Kourlaba & Dennis Cokkinos & Aggeliki Angeli & John Kyriopoulos - 667-675 Competition in prescription drug markets: the roles of trademarks, advertising, and generic names
by Roger Feldman & Félix Lobo - 677-695 The effect of stimulants and their combined use with cigarettes on mortality: the case of betel quid
by Shao-Hsun Keng & Sheng-Jang Sheu - 697-702 The effect of chronic conditions on stated preferences for health
by A. Pickard & Rima Tawk & James Shaw - 703-705 Do patients registered with CAM-trained GPs really use fewer health care resources and live longer? A response to Kooreman and Baars. Eur J Health Econ (2012). 13:469–776
by Christopher Sampson & David Whitehurst & Andrew Street - 707-708 Do patients registered with CAM-trained GPs really use fewer health care resources and live longer? A reply to Christopher James Sampson
by Peter Kooreman & Erik Baars
June 2013, Volume 14, Issue 3
- 363-366 HAS to be NICE?
by Gérard Pouvourville - 367-372 Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement
by Don Husereau & Michael Drummond & Stavros Petrou & Chris Carswell & David Moher & Dan Greenberg & Federico Augustovski & Andrew Briggs & Josephine Mauskopf & Elizabeth Loder - 373-381 Redistributional consequences of early childhood intervention
by Tim Lohse & Peter Lutz & Christian Thomann - 383-390 Problems of priority change in kidney allocation and beyond
by Marlies Ahlert & Hartmut Kliemt - 391-406 Bargaining and the provision of health services
by Luigi Siciliani & Anderson Stanciole - 407-413 Terminal patients in Belgian nursing homes: a cost analysis
by Steven Simoens & Betty Kutten & Emmanuel Keirse & Paul Berghe & Claire Beguin & Marianne Desmedt & Myriam Deveugele & Christian Léonard & Dominique Paulus & Johan Menten - 415-429 Effects of competition on hospital quality: an examination using hospital administrative data
by Alfons Palangkaraya & Jongsay Yong - 431-442 Welfare-related health inequality: does the choice of measure matter?
by Joachim Frick & Nicolas Ziebarth - 443-455 Diffusion of innovations in social interaction systems. An agent-based model for the introduction of new drugs in markets
by Julio Pombo-Romero & Luis Varela & Carlos Ricoy - 457-469 Does the US health care safety net discourage private insurance coverage?
by Xuezheng Qin & Gordon Liu - 471-479 The impact of time cost of physical exercise on health outcomes by older adults: the DR’s EXTRA Study
by Virpi Kuvaja-Köllner & Hannu Valtonen & Pirjo Komulainen & Maija Hassinen & Rainer Rauramaa - 481-493 Cost-effectiveness analysis of dronedarone versus other anti-arrhythmic drugs for the treatment of atrial fibrillation—results for Canada, Italy, Sweden and Switzerland
by Jonas Nilsson & Örjan Åkerborg & Gaëlle Bégo-Le Bagousse & Mårten Rosenquist & Peter Lindgren - 495-502 Drug expenditure of high-cost patients and their characteristics in Finland
by Leena Saastamoinen & Jouko Verho - 503-506 Systems GMM estimates of the health care spending and GDP relationship: a note
by Saten Kumar - 507-514 Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales
by Ruth Brown & Sean Stern & Sujith Dhanasiri & Steve Schey - 515-526 Inter-regional competition and quality in hospital care
by Hiroshi Aiura - 527-538 Spending more money, saving more lives? The relationship between avoidable mortality and healthcare spending in 14 countries
by Richard Heijink & Xander Koolman & Gert Westert - 539-550 Can EQ-5D and 15D be used interchangeably in economic evaluations? Assessing quality of life in post-stroke patients
by Lene Lunde - 551-568 How to use pharmacy claims data to measure patient nonadherence? The example of oral diabetics in therapy of type 2 diabetes mellitus
by Thomas Wilke & Antje Groth & Sabrina Mueller & Dallas Reese & Roland Linder & Susanne Ahrens & Frank Verheyen
April 2013, Volume 14, Issue 2
- 153-159 Resource allocation strategies in Southeastern European health policy
by Mihajlo Jakovljevic - 161-170 Self-control and support for anti-smoking policies among smokers, ex smokers, and never smokers
by Lourdes Badillo Amador & Ángel López Nicolás - 171-183 The welfare implications of disability for older people in Ireland
by John Cullinan & Brenda Gannon & Eamon O’Shea - 185-195 Economic evaluation of URMEL-ICE, a school-based overweight prevention programme comprising metabolism, exercise and lifestyle intervention in children
by Dorothea Kesztyüs & Anja Schreiber & Tamara Wirt & Martina Wiedom & Jens Dreyhaupt & Susanne Brandstetter & Benjamin Koch & Olivia Wartha & Rainer Muche & Martin Wabitsch & Reinhold Kilian & Jürgen Steinacker - 197-209 The impact of using different tariffs to value EQ-5D health state descriptions: an example from a study of acute cough/lower respiratory tract infections in seven countries
by Raymond Oppong & Billingsley Kaambwa & Jacqueline Nuttall & Kerenza Hood & Richard Smith & Joanna Coast - 211-219 Trends in social class inequalities in the use of health care services within the Spanish National Health System, 1993–2006
by Laia Palència & Albert Espelt & Maica Rodríguez-Sanz & Katia B. Rocha & M. Isabel Pasarín & Carme Borrell - 221-230 An analysis of the influence of framework aspects on the study design of health economic modeling evaluations
by Sebastian Gurtner - 231-241 Mapping utility scores from the Barthel index
by Billingsley Kaambwa & Lucinda Billingham & Stirling Bryan - 243-252 The influence of social deprivation on length of hospitalisation
by Engin Yilmaz & Denis Raynaud - 253-265 Determinants of healthcare system’s efficiency in OECD countries
by Sharon Hadad & Yossi Hadad & Tzahit Simon-Tuval - 267-276 Organisational determinants of production and efficiency in general practice: a population-based study
by Kim Olsen & Dorte Gyrd-Hansen & Torben Sørensen & Troels Kristensen & Peter Vedsted & Andrew Street - 277-285 Using respondents’ uncertainty scores to mitigate hypothetical bias in community-based health insurance studies
by Hermann Donfouet & Pierre-Alexandre Mahieu & Eric Malin - 287-295 Endogenous technological change in medicine and its impact on healthcare costs: evidence from the pharmaceutical market in Taiwan
by Chee-Ruey Hsieh & Ya-Ming Liu & Chia-Lin Chang - 297-306 Moving beyond a limited follow-up in cost-effectiveness analyses of behavioral interventions
by Rilana Prenger & Marcel Pieterse & Louise Braakman-Jansen & Job Palen & Lieke Christenhusz & Erwin Seydel - 307-314 Longitudinal predictive ability of mapping models: examining post-intervention EQ-5D utilities derived from baseline MHAQ data in rheumatoid arthritis patients
by Nick Kontodimopoulos & Panagiotis Bozios & John Yfantopoulos & Dimitris Niakas - 315-321 Rationing and deprivation: disease-modifying therapies for multiple sclerosis in the United Kingdom
by Trudy Owens & Nikos Evangelou & David Whynes - 323-344 The impact of health insurance mandates on drug innovation: evidence from the United States
by Natalie Chun & Minjung Park - 345-355 Impact of parallel trade on pharmaceutical firm’s profits: rise or fall?
by Shen Guo & Bin Hu & Hai Zhong - 357-360 The Grossman model after 40 years: a reply to Peter Zweifel
by Robert Kaestner - 361-362 The Grossman model after 40 years: response to Robert Kaestner
by Peter Zweifel
July 2013, Volume 14, Issue 1
- 1-3 The development of new research methods for the valuation of EQ-5D-5L
by Nancy Devlin & Paul Krabbe - 5-13 Introducing the composite time trade-off: a test of feasibility and face validity
by Bas Janssen & Mark Oppe & Matthijs Versteegh & Elly Stolk - 15-24 The effects of lead time and visual aids in TTO valuation: a study of the EQ-VT framework
by Nan Luo & Minghui Li & Elly Stolk & Nancy Devlin - 25-31 Lead versus lag-time trade-off variants: does it make any difference?
by Federico Augustovski & Lucila Rey-Ares & Vilma Irazola & Mark Oppe & Nancy Devlin - 33-42 Dealing with the health state ‘dead’ when using discrete choice experiments to obtain values for EQ-5D-5L heath states
by Juan Ramos-Goñi & Oliver Rivero-Arias & María Errea & Elly Stolk & Michael Herdman & Juan Cabasés - 43-51 Time to tweak the TTO: results from a comparison of alternative specifications of the TTO
by Matthijs Versteegh & Arthur Attema & Mark Oppe & Nancy Devlin & Elly Stolk - 53-64 Time trade-off: one methodology, different methods
by Arthur Attema & Yvette Edelaar-Peeters & Matthijs Versteegh & Elly Stolk - 65-73 One-to-one versus group setting for conducting computer-assisted TTO studies: findings from pilot studies in England and the Netherlands
by Koonal Shah & Andrew Lloyd & Mark Oppe & Nancy Devlin
February 2013, Volume 14, Issue 1
- 1-4 Paying doctors for performance
by Gérard Pouvourville - 5-10 Is health care a luxury or a necessity or both? Evidence from Turkey
by Nilgun Yavuz & Veli Yilanci & Zehra Ozturk - 11-19 Measuring health outcomes of adolescents: report from a pilot study
by Yemi Oluboyede & Sandy Tubeuf & Chris McCabe - 21-39 Federal state differentials in the efficiency of health production in Germany: an artifact of spatial dependence?
by Stefan Felder & Harald Tauchmann - 41-56 The impact of new (orphan) drug approvals on premature mortality from rare diseases in the United States and France, 1999–2007
by Frank Lichtenberg - 57-66 Valuing EQ-5D using Time Trade-Off in France
by Julie Chevalier & Gérard Pouvourville - 67-73 What can we learn from international comparisons of costs by DRG?
by M. Pirson & L. Schenker & D. Martins & Duong Dung & J. Chalé & P. Leclercq - 75-84 Determinants of household direct and indirect costs: an insight for health-seeking behaviour in Burkina Faso
by Tin Su & Steffen Flessa - 85-94 A cost-effectiveness analysis of the Incredible Years parenting programme in reducing childhood health inequalities
by Donal O’Neill & Sinéad McGilloway & Michael Donnelly & Tracey Bywater & Paul Kelly - 95-105 Body weight and health-related quality of life in Catalonia, Spain
by Juan Oliva-Moreno & Ana Gil-Lacruz - 107-115 Balancing equity and efficiency in the Dutch basic benefits package using the principle of proportional shortfall
by E. Wetering & E. Stolk & N. Exel & W. Brouwer - 117-131 Key issues in the design of pay for performance programs
by Frank Eijkenaar - 133-151 Food prices and overweight patterns in Italy
by L. Pieroni & D. Lanari & L. Salmasi
December 2012, Volume 13, Issue 6
- 677-682 The Grossman model after 40 years
by Peter Zweifel - 683-705 Informal caring-time and caregiver satisfaction
by Miriam Marcén & José Molina - 707-722 Measuring attitude toward social health insurance
by Chung-Ping Loh & Katrin Nihalani & Oliver Schnusenberg - 723-740 The use of cost per life year gained as a measurement of cost-effectiveness in Spain: a systematic review of recent publications
by José Rodríguez Barrios & Ferran Pérez Alcántara & Carlos Crespo Palomo & Paloma González García & Enrique Antón De Las Heras & Max Brosa Riestra - 741-754 Health care usage among immigrants and native-born elderly populations in eleven European countries: results from SHARE
by Aïda Solé-Auró & Montserrat Guillén & Eileen Crimmins - 755-767 Economic evaluation of pay-for-performance in health care: a systematic review
by Martin Emmert & Frank Eijkenaar & Heike Kemter & Adelheid Esslinger & Oliver Schöffski - 769-776 Patients whose GP knows complementary medicine tend to have lower costs and live longer
by Peter Kooreman & Erik Baars - 777-788 Paying informally in the Albanian health care sector: a two-tiered stochastic frontier model
by Sonila Tomini & Wim Groot & Milena Pavlova - 789-799 The cost-effectiveness of cash versus lottery incentives for a web-based, stated-preference community survey
by Aleksandra Gajic & David Cameron & Jeremiah Hurley - 801-809 Cost effectiveness of golimumab for the treatment of active psoriatic arthritis
by Ewen Cummins & Christian Asseburg & Manishi Prasad & Jacqueline Buchanan & Yogesh Punekar - 811-818 Favourable cost-benefit in an early defibrillation programme using dual dispatch of ambulance and fire services in out-of-hospital cardiac arrest
by Björn Sund & Leif Svensson & Mårten Rosenqvist & Jacob Hollenberg - 819-826 Epilepsy in Sweden: health care costs and loss of productivity—a register-based approach
by Kristian Bolin & Anders Lundgren & Fredrik Berggren & Kristina Källén
October 2012, Volume 13, Issue 5
- 525-531 Health economics and health technology assessment in Central and Eastern Europe: a dose of reality
by L. Gulácsi & E. Orlewska & M. Péntek - 533-548 Assessing preferences for improved smoking cessation medications: a discrete choice experiment
by Joachim Marti - 549-560 Cost-effectiveness of open versus laparoscopic appendectomy: a multilevel approach with propensity score matching
by Laura Haas & Tom Stargardt & Jonas Schreyoegg - 561-568 Disease progression and costs of care in Alzheimer’s disease patients treated with donepezil: a longitudinal naturalistic cohort
by Anders Gustavsson & Linus Jönsson & Johan Parmler & Niels Andreasen & Carina Wattmo & Åsa Wallin & Lennart Minthon - 569-574 Does participation in clinical trials influence the costs of future management of patients?
by Anne Hvenegaard & Henrik Juhl & Andreas Habicht - 575-587 Comparison of health state utility values derived using time trade-off, rank and discrete choice data anchored on the full health-dead scale
by John Brazier & Donna Rowen & Yaling Yang & Aki Tsuchiya - 589-603 Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab
by Thomas Delea & Paul Tappenden & Oleg Sofrygin & Dominy Browning & Mayur Amonkar & Jon Karnon & Mel Walker & David Cameron - 605-614 Loss of labour productivity caused by disease and health problems: what is the magnitude of its effect on Spain’s Economy?
by Juan Oliva-Moreno - 615-621 Private health insurance: a role model for European health systems
by Christine Arentz & Johann Eekhoff & Susanna Kochskämper - 623-634 The sustainability of European health care systems: beyond income and aging
by Fabio Pammolli & Massimo Riccaboni & Laura Magazzini - 635-649 Medical guidelines, physician density, and quality of care: evidence from German SHARE data
by Hendrik Jürges & Vincent Pohl - 651-661 Genetic testing in the European Union: does economic evaluation matter?
by Fernando Antoñanzas & R. Rodríguez-Ibeas & M. Hutter & R. Lorente & C. Juárez & M. Pinillos - 663-676 The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country
by Mehlika Toy & Fatih Onder & Ramazan Idilman & Gokhan Kabacam & Jan Richardus & Mithat Bozdayi & Meral Akdogan & Zarife Kuloglu & Aydan Kansu & Solko Schalm & Cihan Yurdaydin
August 2012, Volume 13, Issue 4
- 375-378 Coping with uncertainty on health decisions: assessing new solutions
by Fernando Antoñanzas & Roberto Rodríguez-Ibeas & Carmelo Juárez-Castelló - 379-380 The cost-effectiveness of tiotropium for the treatment of chronic obstructive pulmonary disease (COPD): the importance of the comparator
by Mattias Neyt & Ann Den Bruel - 381-391 Cost-effectiveness of adjunctive eptifibatide in patients undergoing coronary stenting in Germany
by Sarah Dewilde & Bernd Brüggenjürgen & Christoph Nienaber & Jochen Senges & Robert Welte & Stefan Willich - 393-407 In with the new: the determinants of prescribing innovation by general practitioners in Ireland
by Jane Bourke & Stephen Roper - 409-417 On the meaningfulness of testing preference axioms in stated preference discrete choice experiments
by Jens Hougaard & Tue Tjur & Lars Østerdal - 419-427 Factors determining access to and use of primary health care services in the Girona Health Region (Spain)
by Carme Saurina & Laura Vall-llosera & Marc Saez - 429-443 Relative cost effectiveness of the SPHERE intervention in selected patient subgroups with existing coronary heart disease
by Paddy Gillespie & Eamon O’Shea & Andrew Murphy & Susan Smith & Mary Byrne & Molly Byrne & Margaret Cupples - 445-450 Cost–effectiveness of statins revisited: lessons learned about the value of innovation
by Peter Lindgren & Bengt Jönsson - 451-460 The effect of health shocks on smoking and obesity
by Leonie Sundmacher - 461-490 The trade-off between formal and informal care in Spain
by Sergi Jiménez-Martín & Cristina Prieto - 491-500 The way that you do it? An elaborate test of procedural invariance of TTO, using a choice-based design
by Arthur Attema & Werner Brouwer - 501-510 A proposed model for economic evaluations of major depressive disorder
by Hossein Haji Ali Afzali & Jonathan Karnon & Jodi Gray - 511-524 Cost of care for colorectal cancer in Ireland: a health care payer perspective
by L. Tilson & L. Sharp & C. Usher & C. Walsh & Whyte S & A. O’Ceilleachair & C. Stuart & B. Mehigan & M. John Kennedy & P. Tappenden & J. Chilcott & A. Staines & H. Comber & M. Barry
June 2012, Volume 13, Issue 3
- 223-226 Time to incorporate time in cost-effectiveness analysis
by Gijs Wetering & Willem Woertman & Eddy Adang - 227-236 Smoking bans and the secondhand smoking problem: an economic analysis
by Annette Hofmann & Martin Nell - 237-250 Incremental net benefit and acceptability of alternative health policies: a case study of mass screening for colorectal cancer
by Pauline Chauvin & Jean-Michel Josselin & Denis Heresbach - 251-265 I feel good! Gender differences and reporting heterogeneity in self-assessed health
by Udo Schneider & Christian Pfarr & Brit Schneider & Volker Ulrich - 267-276 Socioeconomic analysis of patient-centric networks: effects of patients and hospitals’ characteristics and network structure on hospitalization costs
by Alireza Abbasi & Shahadat Uddin & Liaquat Hossain - 277-287 The demand for sports and exercise: results from an illustrative survey
by Nana Anokye & Subhash Pokhrel & Martin Buxton & Julia Fox-Rushby - 289-300 Cancer patients’ willingness to pay for blood transfusions at home: results from a contingent valuation study in a French cancer network
by Nathalie Havet & Magali Morelle & Raphaël Remonnay & Marie-Odile Carrere - 301-313 Patient socioeconomic determinants of the choice of generic versus brand name drugs in the context of a reference price system: evidence from Belgian prescription data
by Maria-Isabel Farfan-Portet & Carine Van de Voorde & France Vrijens & Robert Vander Stichele - 315-325 Patient socioeconomic determinants for the choice of the cheapest molecule within a cluster: evidence from Belgian prescription data
by France Vrijens & Carine Van de Voorde & Maria-Isabel Farfan-Portet & Robert Vander Stichele - 327-336 Formal and informal care for disabled elderly living in the community: an appraisal of French care composition and costs
by Alain Paraponaris & Bérengère Davin & Pierre Verger - 337-346 Impact of healthcare reforms on out-of-pocket health expenditures in Turkey for public insurees
by Burcay Erus & Nazli Aktakke - 347-353 Lifetime costs of the top five cancers in Taiwan
by Hui-Chu Lang & Shi-Liang Wu - 355-363 Association of antipsychotic polypharmacy with health service cost: a register-based cost analysis
by Lone Baandrup & Jan Sørensen & Henrik Lublin & Merete Nordentoft & Birte Glenthoj - 365-374 Cost-effectiveness of extended-release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany
by Galin Michailov & Glenn Davies & Karl Krobot
April 2012, Volume 13, Issue 2
- 121-126 Separating the wheat from the chaff
by Claus Runge - 127-144 Towards a social discount rate for the economic evaluation of health technologies in Germany: an exploratory analysis
by Mareike Schad & Jürgen John - 145-156 Cost-effectiveness of treatment with etanercept for psoriasis in Sweden
by Christopher Knight & Josephine Mauskopf & Mats Ekelund & Amitabh Singh & Shiyi Yang & Robert Boggs - 157-167 Malpractice liability, technology choice and negative defensive medicine
by Eberhard Feess - 169-180 Decision-making in general practice: the effect of financial incentives on the use of laboratory analyses
by Siri Munkerud - 181-192 Treating pneumonia in critical care in the United Kingdom following failure of initial antibiotic: a cost-utility analysis comparing meropenem with piperacillin/tazobactam
by Steven Edwards & Sarah Wordsworth & Mike Clarke - 193-202 Exploring the disparities of regional health care expenditures in Switzerland: some empirical evidence
by Oliver Reich & Cornelia Weins & Claudia Schusterschitz & Magdalena Thöni - 203-221 Defining care products to finance health care in the Netherlands
by Machiel Westerdijk & Joost Zuurbier & Martijn Ludwig & Sarah Prins
February 2012, Volume 13, Issue 1
- 1-5 Is it time to reconsider the role of patient co-payments for pharmaceuticals in Europe?
by Michael Drummond & Adrian Towse - 7-18 The convergence of health care financing structures: empirical evidence from OECD-countries
by Andrea Leiter & Engelbert Theurl - 19-27 Decomposing the determinants of health care expenditure: the case of Spain
by David Prieto & Santiago Lago-Peñas - 29-38 The impact of presumed consent laws and institutions on deceased organ donation
by Fırat Bilgel - 39-50 The impact of BMI on direct costs in Children and Adolescents: empirical findings for the German Healthcare System based on the KiGGS-study
by Christina Wenig - 51-62 Spillover effects of supplementary on basic health insurance: evidence from the Netherlands
by Anne-Fleur Roos & Frederik Schut - 63-70 Future costs in cost-effectiveness analysis: an empirical assessment
by Marie Kruse & Jan Sørensen & Dorte Gyrd-Hansen - 71-80 Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy
by O. Zaniolo & S. Iannazzo & L. Pradelli & M. Miravitlles - 81-91 The cost of multiple sclerosis in Norway
by B. Svendsen & K.-M. Myhr & H. Nyland & J. Aarseth - 93-99 Do smoke-free laws affect revenues in pubs and restaurants?
by Hans Melberg & Karl Lund - 101-110 Cost-effectiveness model for a specific mixture of prebiotics in The Netherlands
by I. Lenoir-Wijnkoop & W. Aalderen & G. Boehm & D. Klaassen & A. Sprikkelman & M. Nuijten - 111-120 Comparing the sensitivity of EQ-5D, SF-6D and 15D utilities to the specific effect of diabetic complications
by Nick Kontodimopoulos & Evelina Pappa & Zinovia Chadjiapostolou & Eleni Arvanitaki & Angelos Papadopoulos & Dimitris Niakas
December 2011, Volume 12, Issue 6
- 499-502 Budget impact analysis in economic evaluation: a proposal for a clearer definition
by Livio Garattini & Katelijne Vooren - 503-508 Comparison of cost-weights scales methodologies in the perspective of a financing system based on pathologies
by M. Pirson & C. Delo & D. Martins & P. Leclercq - 509-519 Cost efficiency of university hospitals in the Nordic countries: a cross-country analysis
by Emma Medin & Kjartan Anthun & Unto Häkkinen & Sverre Kittelsen & Miika Linna & Jon Magnussen & Kim Olsen & Clas Rehnberg - 521-531 Do you believe in magic? Improving the quality of pharmacy services through restricting entry and aspirational contracts, the Irish experience
by Paul Gorecki - 533-539 Direct costs of Alzheimer’s disease in Germany
by Peter Kiencke & Dietmar Daniel & Christine Grimm & Reinhard Rychlik - 541-551 Exploring the relationship between costs and quality: Does the joint evaluation of costs and quality alter the ranking of Danish hospital departments?
by Anne Hvenegaard & Jacob Arendt & Andrew Street & Dorte Gyrd-Hansen - 553-562 How removing prescription drugs from reimbursement lists increases the pharmaceutical expenditures for alternatives
by Özden Gür Ali & Başak Topaler - 563-573 The impact of repeated cost containment policies on pharmaceutical expenditure: experience in Spain
by Iván Moreno-Torres & Jaume Puig-Junoy & Josep Raya - 575-588 Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom
by M. Botteman & M. Meijboom & I. Foley & J. Stephens & Y. Chen & S. Kaura - 589-603 Market structure and hospital–insurer bargaining in the Netherlands
by R. Halbersma & M. Mikkers & E. Motchenkova & I. Seinen
October 2011, Volume 12, Issue 5
- 393-395 Pharmaceutical patents, R&D incentives and access to new drugs: new ways of progress at the crossroad
by Fernando Antoñanzas & Carmelo Juárez-Castelló & Roberto Rodríguez-Ibeas - 397-404 Largely ignored: the impact of the threshold value for a QALY on the importance of a transferability factor
by Pepijn Vemer & Maureen Rutten-van Mölken - 405-416 Discrimination in waiting times by insurance type and financial soundness of German acute care hospitals
by Christoph Schwierz & Achim Wübker & Ansgar Wübker & Björn Kuchinke - 417-427 Hospital’s activity-based financing system and manager: physician interaction
by David Crainich & Hervé Leleu & Ana Mauleon - 429-444 Contractual conditions, working conditions and their impact on health and well-being
by Silvana Robone & Andrew Jones & Nigel Rice - 445-453 Comparing top-down and bottom-up costing approaches for economic evaluation within social welfare
by Tina Olsson - 455-467 Cost of low back pain in Switzerland in 2005
by Simon Wieser & Bruno Horisberger & Sara Schmidhauser & Claudia Eisenring & Urs Brügger & Andreas Ruckstuhl & Jürg Dietrich & Anne Mannion & Achim Elfering & Özgür Tamcan & Urs Müller - 469-478 Ageing and health care expenditure in EU-15
by Mickael Bech & Terkel Christiansen & Ehsan Khoman & Jørgen Lauridsen & Martin Weale - 479-487 Atrial fibrillation: the cost of illness in Sweden
by Lisa Ericson & Lennart Bergfeldt & Ingela Björholt - 489-497 Cost-effectiveness of cognitive-behavioral group therapy for dysfunctional fear of progression in cancer patients
by C. Sabariego & M. Brach & P. Herschbach & P. Berg & G. Stucki
August 2011, Volume 12, Issue 4
- 285-288 What values do the public want their health care systems to use in evaluating technologies?
by Martin Buxton & James Chambers - 289-295 Estimates of patient costs related with population morbidity: can indirect costs affect the results?
by M. Carreras & M. García-Goñi & P. Ibern & J. Coderch & L. Vall-Llosera & J. Inoriza - 297-309 Incentives in primary care and their impact on potentially avoidable hospital admissions
by Gianluca Fiorentini & Elisa Iezzi & Matteo Lippi Bruni & Cristina Ugolini - 311-317 The costs of breast cancer prior to and following diagnosis
by Steven Broekx & Elly Hond & Rudi Torfs & Anne Remacle & Raf Mertens & Thomas D’Hooghe & Patrick Neven & Marie-Rose Christiaens & Steven Simoens - 319-329 Resource use and costs of treating acute cough/lower respiratory tract infections in 13 European countries: results and challenges
by Raymond Oppong & Joanna Coast & Kerry Hood & Jacqui Nuttall & Richard Smith & Christopher Butler - 331-344 Age effects in monetary valuation of reduced mortality risks: the relevance of age-specific hazard rates
by Andrea Leiter - 345-352 Health burden and costs of obesity and overweight in Germany
by A. Konnopka & M. Bödemann & H.-H. König - 353-361 Additional costs of inpatient malnutrition, Victoria, Australia, 2003–2004
by D. Rowell & T. Jackson - 363-371 Cost study of the clinical management of prostate cancer in France: results on the basis of population-based data
by Laurent Molinier & Christel Castelli & Eric Bauvin & Xavier Rebillard & Michel Soulié & Jean-Pierre Daurès & Pascale Grosclaude - 373-381 Factors associated with the use of primary care services: the role of practice nurses
by Laura Vallejo-Torres & Stephen Morris - 383-391 The impact of disease severity on EQ-5D and SF-6D utility discrepancies in chronic heart failure
by Nick Kontodimopoulos & Michalis Argiriou & Nikolaos Theakos & Dimitris Niakas
June 2011, Volume 12, Issue 3
- 189-191 To model or not to model: lessons from two vaccinations
by Livio Garattini & Anna Padula - 193-203 Analysis of physicians’ perspectives versus patients’ preferences: direct assessment and discrete choice experiments in the therapy of multiple myeloma
by Axel Mühlbacher & Matthias Nübling - 205-218 Modelling the costs of care of hypertension in patients with metabolic syndrome and its consequences, in Germany, Spain and Italy
by Eberhard Wille & Jürgen Scholze & Eduardo Alegria & Claudio Ferri & Sue Langham & Warren Stevens & David Jeffries & Kerstin Uhl-Hochgraeber - 219-230 Utilities and disutilities for attributes of injectable treatments for type 2 diabetes
by Kristina Boye & Louis Matza & Kimberly Walter & Kate Brunt & Andrew Palsgrove & Aodan Tynan - 231-241 Practical issues in handling data input and uncertainty in a budget impact analysis
by M. Nuijten & T. Mittendorf & U. Persson - 243-252 Deriving reference values and utilities for the QoL-AGHDA in adult GHD
by J. Busschbach & B. Wolffenbuttel & L. Annemans & W. Meerding & M. Kołtowska-Häggström - 253-261 Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece
by Nikos Maniadakis & Mattias Ekman & Vasilios Fragoulakis & Vasiliki Papagiannopoulou & John Yfantopoulos - 263-271 Reimbursement of pharmaceuticals: reference pricing versus health technology assessment
by Michael Drummond & Bengt Jönsson & Frans Rutten & Tom Stargardt - 273-283 Health care costs and their predictors of inflammatory bowel diseases in Germany
by Anne Prenzler & Bernd Bokemeyer & J.-Matthias Schulenburg & Thomas Mittendorf
April 2011, Volume 12, Issue 2
- 97-102 Relative effectiveness and the European pharmaceutical market
by Bengt Jönsson - 103-113 The effect of alcoholic beverage excise tax on alcohol-attributable injury mortalities
by Chong Son & Kudret Topyan - 115-125 Technical efficiency in primary health care: does quality matter?
by Luis Murillo-Zamorano & Carmelo Petraglia - 127-140 Economic policies for healthier food intake: the impact on different household categories
by Jonas Nordström & Linda Thunström - 141-162 Analysis of the validity of the vignette approach to correct for heterogeneity in reporting health system responsiveness
by Nigel Rice & Silvana Robone & Peter Smith - 163-174 Severity as an independent determinant of the social value of a health service
by Jeff Richardson & John McKie & Stuart Peacock & Angelo Iezzi - 175-188 Trust on doctor, social capital and medical care use of the elderly
by Jae-Young Lim & Hyun-Hoon Lee & Yeon-Hee Hwang
February 2011, Volume 12, Issue 1
- 1-1 Letter from the editors
by J.-Matthias Graf von der Schulenburg & Wolfgang Greiner - 3-16 Public health care providers and market competition: the case of Finnish occupational health services
by Eila Kankaanpää & Ismo Linnosmaa & Hannu Valtonen - 17-28 Inequalities in the use of health services between immigrants and the native population in Spain: what is driving the differences?
by Dolores Jiménez-Rubio & Cristina Hernández-Quevedo - 29-38 Health care expenditures and gross domestic product: the Turkish case
by Seher Sülkü & Asena Caner - 39-47 Optimal deductibles for outpatient services
by Karl-Michael Ortmann - 49-59 Generic substitution: micro evidence from register data in Norway
by Dag Dalen & Kari Furu & Marilena Locatelli & Steinar Strøm - 61-77 Social health inequalities among older Europeans: the contribution of social and family background
by Sandy Tubeuf & Florence Jusot - 79-85 Risk and uncertainty in health investment
by Takao Asano & Akihisa Shibata - 87-95 Preferences for health insurance and health status: does it matter whether you are Dutch or German?
by Janet Vroomen & Peter Zweifel
December 2010, Volume 11, Issue 6
- 521-523 A French approach to cost-effectiveness analysis?
by Gérard Pouvourville